Genetics: Discovering the Unknown in Breast Cancer

Article

For this month’s episode, we spoke with Katherine Crew, MD, an associate professor of medicine and epidemiology at the Columbia University Herbert Irving Comprehensive Cancer Center. Crew discusses her recent research on genetic testing in young women with breast cancer. While she was happy to see that the testing rates were not much different between ethnic groups, there were some differences when it came to the results.

Crew also offers advice for nurses in discussing genetics with their patients, as well as easing the worry of not knowing what some genetic testing results may mean.

Related Videos
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Pattie Jakel
Christine Wylie
Daly
Grace Choong
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Expert in oncology
Expert in oncology
Experts in oncology
Related Content
dna genetics genomic tests © marina zlochin -adobe.stock.com.png

Out-of-Pocket Costs, Insurance Status May Impact Genomic Testing Rates

April 10th 2024
Article

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

FDA Accepts BLA for Dato-Dxd in HR+/HER2– Metastatic Breast Cancer

FDA Accepts BLA for Dato-Dxd in HR+/HER2– Metastatic Breast Cancer

April 3rd 2024
Article

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

FDA Approves Fluorouracil Safety Label Update Regarding DPD Deficiency Use

FDA Approves Fluorouracil Safety Label Update Regarding DPD Deficiency Use

March 22nd 2024
Article

The safety label for fluorouracil products will now include information about the agent’s use in patients with dihydropyrimidine dehydrogenase deficiency.

Understanding the ‘Excitement’ Around ADCs for HR+/HER2– Breast Cancer

Understanding the ‘Excitement’ Around ADCs for HR+/HER2– Breast Cancer

March 13th 2024
Article

With the progress made with ADCs, there is interest in moving these agents up in the treatment paradigm for HR-positive/HER2-negative breast cancer.

© 2024 MJH Life Sciences

All rights reserved.